Short Interest in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Increases By 954.2%

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,057,055 shares, an increase of 954.2% from the December 15th total of 100,272 shares. Based on an average daily volume of 10,593,738 shares, the short-interest ratio is presently 0.1 days. Approximately 42.9% of the shares of the company are sold short. Approximately 42.9% of the shares of the company are sold short. Based on an average daily volume of 10,593,738 shares, the short-interest ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on EKSO shares. Wall Street Zen raised shares of Ekso Bionics to a “hold” rating in a report on Saturday, December 13th. HC Wainwright cut shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 31st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ekso Bionics in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $10.50.

Insider Activity at Ekso Bionics

In other news, CFO Jerome Wong sold 11,288 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $4.80, for a total transaction of $54,182.40. Following the completion of the sale, the chief financial officer owned 26,009 shares in the company, valued at approximately $124,843.20. This represents a 30.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Scott G. Davis sold 23,315 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $4.80, for a total value of $111,912.00. Following the completion of the sale, the chief executive officer owned 78,777 shares of the company’s stock, valued at $378,129.60. The trade was a 22.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Ekso Bionics

Hedge funds have recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in shares of Ekso Bionics during the 3rd quarter valued at $57,000. Shay Capital LLC bought a new stake in shares of Ekso Bionics during the 3rd quarter valued at $67,000. Citadel Advisors LLC bought a new position in Ekso Bionics during the 3rd quarter valued at approximately $198,000. Finally, Consolidated Portfolio Review Corp bought a new position in shares of Ekso Bionics in the third quarter worth approximately $333,000. Hedge funds and other institutional investors own 6.42% of the company’s stock.

Ekso Bionics Trading Down 2.1%

EKSO traded down $0.17 during trading on Wednesday, reaching $8.05. 25,073 shares of the company’s stock were exchanged, compared to its average volume of 542,310. The company has a current ratio of 1.66, a quick ratio of 1.09 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $21.09 million, a PE ratio of -1.41 and a beta of 0.71. The firm has a fifty day moving average price of $5.59 and a two-hundred day moving average price of $4.65. Ekso Bionics has a one year low of $2.73 and a one year high of $12.70.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Tuesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.45. Ekso Bionics had a negative net margin of 70.74% and a negative return on equity of 90.71%. The company had revenue of $4.23 million for the quarter, compared to the consensus estimate of $4.16 million. As a group, equities research analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

About Ekso Bionics

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.